Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
Heart Fail Rev
; 21(6): 699-701, 2016 11.
Article
em En
| MEDLINE
| ID: mdl-27620301
ABSTRACT
The brand new 2016 ESC guidelines for the treatment of acute and chronic heart failure continue to give a prominent place to mineralocorticoid receptor antagonists in the treatment of chronic heart failure with reduced ejection fraction (HFrEF). In the prevention of HF hospitalization and death, a class I, level of recommendation A, is given to MRAs for patients with HFrEF, who remain symptomatic despite treatment with an ACE-inhibitor and a beta-blocker and have an LVEF below 35 %. This recommendation is primarily based on two landmark trials, the RALES trial (for spironolactone) and the EMPHASIS-HF trial (for eplerenone). A crucial question is, however, why MRAs are advised only in "third place," i.e., after optimal up-titration of ACE-inhibitors and beta-blockers. We wonder whether MRAs could not or should not be given earlier in the treatment of HFrEF, namely before or together with the up-titration of ACE-inhibitors and beta-blockers. Several arguments to support this plea are described in this short paper.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Volume Sistólico
/
Antagonistas de Receptores de Mineralocorticoides
/
Insuficiência Cardíaca
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article